Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression

Hiroto Kaneko, Shigeo Horiike, Hiroyuki Nakai, Yutaka Ueda, Makoto Nakao, Kouichi Hirakawa, Shohei Yokota, Masafumi Taniwaki, Shinichi Misawa, Kei Kashima

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Neurofibromatosis 1 gene (NF1) is a tumor suppressor gene and the product of which down-regulates Nras protein by its GTPase activating protein-related domain (NF1-GRD). Although the incidence of NF1 mutation was reported to be rare in the chronic phase of myelodysplastic syndrome (MDS), there have been no previous reports on its configuration in patients showing the disease progression. We examined NF1 in 50 patients with MDS including 9 who had progressed to more advanced stages and 16 to acute leukemia. Six patients had an Nras mutation. We carried out allele specific restriction analysis (ASRA) to detect a mutation at the first nucleotide A of codon 1423 (AAG), a mutational hot spot. We also employed a polymerase chain reaction mediated single strand conformation polymorphism (PCR-SSCP) method to confirm the result of ASRA and to detect a point mutation in other sequences of FLR exon. In consequence, ASRA disclosed wild type configuration and PCR-SSCP showed no aberrant band in any sample examined whether the samples harboured an Nras mutation or not. We conclude that NF1 mutation does not play a crucial role in the development and the progression of MDS.

Original languageEnglish (US)
Pages (from-to)113-116
Number of pages4
JournalInternational Journal of Hematology
Volume61
Issue number3
StatePublished - Apr 1995
Externally publishedYes

Fingerprint

Neurofibromatosis 1 Genes
Myelodysplastic Syndromes
Disease Progression
Mutation
Alleles
GTPase-Activating Proteins
Polymerase Chain Reaction
Tumor Suppressor Genes
Point Mutation
Codon
Exons
Leukemia
Down-Regulation
Nucleotides
Incidence
Proteins

Keywords

  • Allele specific restriction analysis
  • Myelodysplastic syndrome
  • NF1
  • Single strand conformation polymorphism

ASJC Scopus subject areas

  • Hematology

Cite this

Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression. / Kaneko, Hiroto; Horiike, Shigeo; Nakai, Hiroyuki; Ueda, Yutaka; Nakao, Makoto; Hirakawa, Kouichi; Yokota, Shohei; Taniwaki, Masafumi; Misawa, Shinichi; Kashima, Kei.

In: International Journal of Hematology, Vol. 61, No. 3, 04.1995, p. 113-116.

Research output: Contribution to journalArticle

Kaneko, H, Horiike, S, Nakai, H, Ueda, Y, Nakao, M, Hirakawa, K, Yokota, S, Taniwaki, M, Misawa, S & Kashima, K 1995, 'Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression', International Journal of Hematology, vol. 61, no. 3, pp. 113-116.
Kaneko, Hiroto ; Horiike, Shigeo ; Nakai, Hiroyuki ; Ueda, Yutaka ; Nakao, Makoto ; Hirakawa, Kouichi ; Yokota, Shohei ; Taniwaki, Masafumi ; Misawa, Shinichi ; Kashima, Kei. / Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression. In: International Journal of Hematology. 1995 ; Vol. 61, No. 3. pp. 113-116.
@article{95397d60578f46e595feb36dd3ee675e,
title = "Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression",
abstract = "Neurofibromatosis 1 gene (NF1) is a tumor suppressor gene and the product of which down-regulates Nras protein by its GTPase activating protein-related domain (NF1-GRD). Although the incidence of NF1 mutation was reported to be rare in the chronic phase of myelodysplastic syndrome (MDS), there have been no previous reports on its configuration in patients showing the disease progression. We examined NF1 in 50 patients with MDS including 9 who had progressed to more advanced stages and 16 to acute leukemia. Six patients had an Nras mutation. We carried out allele specific restriction analysis (ASRA) to detect a mutation at the first nucleotide A of codon 1423 (AAG), a mutational hot spot. We also employed a polymerase chain reaction mediated single strand conformation polymorphism (PCR-SSCP) method to confirm the result of ASRA and to detect a point mutation in other sequences of FLR exon. In consequence, ASRA disclosed wild type configuration and PCR-SSCP showed no aberrant band in any sample examined whether the samples harboured an Nras mutation or not. We conclude that NF1 mutation does not play a crucial role in the development and the progression of MDS.",
keywords = "Allele specific restriction analysis, Myelodysplastic syndrome, NF1, Single strand conformation polymorphism",
author = "Hiroto Kaneko and Shigeo Horiike and Hiroyuki Nakai and Yutaka Ueda and Makoto Nakao and Kouichi Hirakawa and Shohei Yokota and Masafumi Taniwaki and Shinichi Misawa and Kei Kashima",
year = "1995",
month = "4",
language = "English (US)",
volume = "61",
pages = "113--116",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression

AU - Kaneko, Hiroto

AU - Horiike, Shigeo

AU - Nakai, Hiroyuki

AU - Ueda, Yutaka

AU - Nakao, Makoto

AU - Hirakawa, Kouichi

AU - Yokota, Shohei

AU - Taniwaki, Masafumi

AU - Misawa, Shinichi

AU - Kashima, Kei

PY - 1995/4

Y1 - 1995/4

N2 - Neurofibromatosis 1 gene (NF1) is a tumor suppressor gene and the product of which down-regulates Nras protein by its GTPase activating protein-related domain (NF1-GRD). Although the incidence of NF1 mutation was reported to be rare in the chronic phase of myelodysplastic syndrome (MDS), there have been no previous reports on its configuration in patients showing the disease progression. We examined NF1 in 50 patients with MDS including 9 who had progressed to more advanced stages and 16 to acute leukemia. Six patients had an Nras mutation. We carried out allele specific restriction analysis (ASRA) to detect a mutation at the first nucleotide A of codon 1423 (AAG), a mutational hot spot. We also employed a polymerase chain reaction mediated single strand conformation polymorphism (PCR-SSCP) method to confirm the result of ASRA and to detect a point mutation in other sequences of FLR exon. In consequence, ASRA disclosed wild type configuration and PCR-SSCP showed no aberrant band in any sample examined whether the samples harboured an Nras mutation or not. We conclude that NF1 mutation does not play a crucial role in the development and the progression of MDS.

AB - Neurofibromatosis 1 gene (NF1) is a tumor suppressor gene and the product of which down-regulates Nras protein by its GTPase activating protein-related domain (NF1-GRD). Although the incidence of NF1 mutation was reported to be rare in the chronic phase of myelodysplastic syndrome (MDS), there have been no previous reports on its configuration in patients showing the disease progression. We examined NF1 in 50 patients with MDS including 9 who had progressed to more advanced stages and 16 to acute leukemia. Six patients had an Nras mutation. We carried out allele specific restriction analysis (ASRA) to detect a mutation at the first nucleotide A of codon 1423 (AAG), a mutational hot spot. We also employed a polymerase chain reaction mediated single strand conformation polymorphism (PCR-SSCP) method to confirm the result of ASRA and to detect a point mutation in other sequences of FLR exon. In consequence, ASRA disclosed wild type configuration and PCR-SSCP showed no aberrant band in any sample examined whether the samples harboured an Nras mutation or not. We conclude that NF1 mutation does not play a crucial role in the development and the progression of MDS.

KW - Allele specific restriction analysis

KW - Myelodysplastic syndrome

KW - NF1

KW - Single strand conformation polymorphism

UR - http://www.scopus.com/inward/record.url?scp=0028965271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028965271&partnerID=8YFLogxK

M3 - Article

C2 - 7599322

AN - SCOPUS:0028965271

VL - 61

SP - 113

EP - 116

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -